Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

LipoFIT Analytic GmbH. (12/21/09). "Press Release: Growth Financing LipoFIT Receives Capital for New Diagnostics. SHS, KfW Bankengruppe and Bayern Kapital Purchase a Nearly 50-percent Share". Tübingen & Regensburg.

Region Region Germany
Organisations Organisation LipoFIT Analytic GmbH
  Today Numares AG
  Group Numares (Group)
  Organisation 2 SHS Gesellschaft für Beteiligungsmanagement mbH
Products Product diagnostics (medical/biological)
  Product 2 NMR spectroscopy
Person Person Pfahlert, Volker (LipoFIT GmbH 201001– Managing Director COO before Roche Diagnostics + Dräger Medical)

o Leading diagnostics manager Volker Pfahlert named COO

o Technology for the analysis of blood and other biological fluids

o Speedy diagnostics for illnesses once difficult to diagnose

LipoFIT Analytic GmbH is receiving growth financing in the amount of €4 million to help it transform an analytical technology developed by researchers at the University of Regensburg into diagnostic products. Funds provided by SHS Gesellschaft für Beteiligungsmanagement, a growth investor located in Tübingen, Germany; KfW Bankengruppe (ERP Startfonds); and Bayern Kapital are being invested in the company, which is located in Regensburg. Volker Pfahlert, formerly Chief Executive at Dräger Medical AG, will add his talents to the management at LipoFIT as COO in charge of strategy, marketing and sales.

The technology of LipoFIT permits very quick analysis of the multitude of contents to be found in a single sample of bodily fluids. With this technology, practically the entirety of a person's metabolism can be determined quickly, precisely, and without great expense. This enables physicians working from complex clinical findings to make quick and finely tuned diagnoses, thereby considerably improving patients' chances of recovery. The scientific basis for this technology is the use of very strong magnetic fields for NMR spectroscopy (nuclear magnetic resonance spectroscopy). Magnetic-resonance tomography is already established as a form of imaging in human medicine. LipoFIT uses considerably stronger magnetic fields, applying these to an analysis of e.g. blood or urine samples. All of the components of the sample are identified simultaneously. Unlike established biological or chemical analytical approaches, the LipoFIT approach has the power of identifying not just individual elements (often with fluctuating levels of precision) but rather entire human metabolic processes - in their entirety, and with a high level of precision. Digital storage of the findings permits access to data for further evaluation and fresh examination later on, e.g. in light of new research findings.

LipoFIT Analytic GmbH was established in 2004 by biophysicists Prof. Dr. Dr. Hans Robert Kalbitzer, Associate Professor Dr. Werner Kremer and CEO Dr. Fritz Huber as a spin-off of the University of Regensburg. All of the partners of the company to date will continue their involvement in the company. In exchange for their investment, the new partners, with SHS Gesellschaft für Beteiligungsmanagement as lead investor, will receive around a 50-percent interest in the company. Fritz Huber will remain as CEO. Currently, the ten staff members at LipoFIT are already generating annual sales of around half a million euro. The company's clients include major corporations in the pharmaceuticals sector, as well as several university clinics. The company anticipates robust growth in the near future.

'We are very pleased that, thanks to the assistance of our investors, we now have the opportunity introduce these processes to the broader market - processes developed over many years' work and trials. The history of LipoFIT demonstrates how top-flight international research can also manifest itself in products and economic success. This drives medical advancements while creating jobs in the region at the same time', LipoFIT founder and CEO Fritz Huber observes with regard to the company's planned growth.

'LipoFIT has enormous market potential. The technology offers a host of new applications that will meet an acute need in the hospital setting while offering genuine progress for patients. We will support the management not just financially but in terms of strategy in staffing as well, to permit broad application of the innovative methods developed by LipoFIT. That we managed to win over Dr. Volker Pfahlert for this company is an
important step in this direction', notes Dr. Bernhard Schirmers, Partner at SHS Gesellschaft für Beteiligungsmanagement, commenting on his company's investment in LipoFIT.

Effective immediately, Dr. Volker Pfahlert will be strengthening LipoFIT as COO. Pfahlert brings a rich résumé of experience in outstanding positions in the medical technology and diagnostics industry. Through the end of 2007, he was Chief Executive at Dräger Medical AG&Co.KG and a member of the Executive Board at Drägerwerk AG. Prior to that, as an
executive at Roche Diagnostics in Switzerland, and in Mannheim and Penzberg, Germany, he headed two divisions: Roche Professional Diagnostics and Roche Applied Sciences. Volker Pfahlert is a lecturer at the University of Mannheim, where he lectures on the application of
concepts in marketing strategy.

'I see in the LipoFIT technology and opportunity to install new standards in diagnostic fields that, to date, have not satisfactorily been covered. I look forward to working in this small yet highly innovative company and am certain that LipoFIT is going to experience strong growth', remarks Volker Pfahlert about his new employer.

About LipoFIT Analytic GmbH

LipoFIT was launched in April 2004 with a new, patented method for routine assessments of the risk of developing atherosclerosis. Based on this expertise, the company has now evolved into Europe's largest provider in the NMR analytics field. LipoFIT specializes in the analysis of hundreds of substances in a wide variety of biological fluids, including, particularly, in high-capacity operation. In addition to this, LipoFIT offers a broad spectrum of ultra-modern analytics services in the medicalpharmacological area.

About Bayern Kapital GmbH

Bayern Kapital was created in 1995 at the initiative of the state government of Bavaria within the framework of its 'Bavarian Future Initiative' as a way of providing investment capital particularly to new and innovative Bavarian companies. To date, Bayern Kapital has invested some €147 m in more than 180 innovative, high-tech companies. Bayern Kapital currently manages a combined fund volume of around €190 m in 8 funds. The aim of the Clusterfonds Innovation managed by Bayern Kapital is to provide financing to emerging technology firms, in tandem with an additional investor (lead investor) whose role it is to help financing recipients develop strategic planning and implementation and identify contacts to potential clients and partners. Investments of up to €2 million are provided in this manner.

About ERP Startfonds at KfW Bankengruppe

Among the investments targeted by KfW Bankengruppe are shares in start-ups, investments in growth, and funds to secure companies operating in Germany. Small and medium-sized enterprises (SMEs) receive funding on particularly favourable terms.

Innovations are keenly important to a dynamic and growing economy. With its ERP-Startfonds, KfW promotes research and development, as well as market introduction of new products, processes or services by new, technology-oriented companies.

About SHS Gesellschaft für Beteiligungsmanagement mbH

Established in Tübingen in 1993, SHS Gesellschaft für Beteiligungsmanagement provides financing and consulting to new companies in the industries of the future, particularly in the healthcare and life sciences areas. With the investment funds it has launched to date, SHS manages around €120 m in investment capital. Lead partners at SHS Gesellschaft für Beteiligungsmanagement are former McKinsey consultants Bernhard Schirmers and Reinhilde Spatscheck, as well as Hubertus Leonhardt, formerly Corporate Finance Project Manager at Arthur Andersen. Investors have provided around €50 m for the current SHS III Fonds. These investors include the European Investment Fund (EIF), through which the SHS fund has received resources from the ERPEIF Fund of Funds, as well as from the 'Competitiveness and Innovation Framework Programme' (CIP) of the European Union, and the KfW Bankengruppe, a pension fund, funds of funds and various businesspersons, family offices and the SHS management team itself.

For more information:
Simon Baumann
t: +49.(0)89. 2000 30-32
f: +49.(0)89. 2000 30-40

Record changed: 2017-04-02


Picture [LSA] – The Business Web Portal 650x89px

More documents for Numares (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top